Post-Hemorrhagic Anemia Treatment Market Size & Share, by Treatment (Blood Transfusion, Surgery, Iron Supplements, Extra Oxygen, Fluids); End-user (Hospitals, Clinics, Ambulatory Surgical Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3784
  • Published Date: Feb 16, 2023
  • Report Format: PDF, PPT

Companies Dominating the Post-Hemorrhagic Anemia Treatment Landscape

top-features-companies
    • Rockwell Medical, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Amgen Inc.
    • Vifor Pharma Management Ltd.
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Johnson & Johnson Services, Inc.
    • AMAG Pharmaceuticals
    • Akebia Therapeutics  

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Pfizer Inc. announced the acquisition of Global Blood Therapeutics, Inc., a leading developer and provider of treatments for SCD patients. With this acquisition, Pfizer aims to advance these treatments in the rare hematology space of sickle cell diseases.

  • F. Hoffmann-La-Roche Ltd. Announced the approval of the European Commission for the expansion of Hemlibra. With this expansion, Roche aims to include bleeding episodes in hemophilia A patients without the use of factor VII inhibitors

     


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3784
  • Published Date: Feb 16, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing number of trauma cases across the globe, and increasing prevalence of bleeding disorders. are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023-2035.

Lack of skilled medical professionals and unawareness of the treatment in underdeveloped countries are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Amgen Inc., Vifor Pharma Management Ltd., F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., AMAG Pharmaceuticals, Akebia Therapeutics, and Rockwell Medical Inc.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by treatment, end user, and by region.

The blood transfusion segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying